Atlas Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Atlas Capital Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.4K	Hold	5,000	–	–	﹤0.01%	671
2025 Q4	$60.7K	Buy	+5,000	New	+$60.7K	0.01%	600
2025 Q2	$46.4K	Hold	5,000	–	–	0.01%	634
2025 Q1	$36.6K	Hold	5,000	–	–	﹤0.01%	664
2024 Q4	$42.7K	Buy	+5,000	New	+$48.8K	0.01%	635
2024 Q3	–	Sell	-5,000	Closed	-$34.2K	–	944
2024 Q2	$34.2K	Buy	+5,000	New	+$30.9K	﹤0.01%	633
2024 Q1	–	Sell	-5,000	Closed	-$22.3K	–	945
2023 Q4	$22.3K	Hold	5,000	–	–	﹤0.01%	681
2023 Q3	$15.7K	Hold	5,000	–	–	﹤0.01%	661
2023 Q2	$25.8K	Hold	5,000	–	–	﹤0.01%	648
2023 Q1	$26.4K	Hold	5,000	–	–	﹤0.01%	644
2022 Q4	$14.1K	Hold	5,000	–	–	﹤0.01%	696
2022 Q3	$20.8K	Hold	5,000	–	–	﹤0.01%	650
2022 Q2	$20.1K	Hold	5,000	–	–	﹤0.01%	681
2022 Q1	$24.8K	Hold	5,000	–	–	﹤0.01%	618
2021 Q4	$34.9K	Hold	5,000	–	–	0.01%	574
2021 Q3	$50K	Hold	5,000	–	–	0.01%	521
2021 Q2	$70.9K	Hold	5,000	–	–	0.01%	494
2021 Q1	$82K	Hold	5,000	–	–	0.02%	438
2020 Q4	$104K	Buy	+5,000	New	+$74.3K	0.02%	391
2020 Q3	–	Sell	-5,000	Closed	-$41.6K	–	500
2020 Q2	$41.6K	Hold	5,000	–	–	0.01%	498
2020 Q1	$24.8K	Hold	5,000	–	–	0.01%	500
2019 Q4	$19.8K	Hold	5,000	–	–	﹤0.01%	546
2019 Q3	$15.2K	Hold	5,000	–	–	﹤0.01%	543
2019 Q2	$22K	Hold	5,000	–	–	0.01%	548
2019 Q1	$19.9K	Hold	5,000	–	–	0.01%	486
2018 Q4	$19.9K	Buy	+5,000	New	+$27.6K	0.01%	467

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Atlas Capital Advisors's OCUL Position: Q1 2026 in Review

Atlas Capital Advisors held its Ocular Therapeutix (OCUL) position steady in Q1 2026 at 5,000 shares worth $42.4K. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Atlas Capital Advisors first reported a position in OCUL in Q4 2018 and has held it in 26 quarters since. The position peaked at $104K in Q4 2020. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Atlas Capital Advisors held 5,000 shares of Ocular Therapeutix worth $42.4K as of Q1 2026.
Atlas Capital Advisors left its Ocular Therapeutix share count unchanged in Q1 2026.
Ocular Therapeutix made up ﹤0.01% of Atlas Capital Advisors's portfolio in Q1 2026, its #671 holding.
Atlas Capital Advisors first reported a position in Ocular Therapeutix in Q4 2018 and has held it in 26 quarters since.
Atlas Capital Advisors's Ocular Therapeutix position peaked at $104K in Q4 2020.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Atlas Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.